BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 24919509)

  • 21. Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml(-1).
    Chen R; Zhou LQ; Cai XB; Xie LP; Huang YR; He DL; Gao X; Xu CL; Ding Q; Wei Q; Yin CJ; Ren SC; Wang FB; Tian Y; Sun ZQ; Fu Q; Ma LL; Zheng JH; Ye ZQ; Ye DW; Xu DF; Hou JQ; Xu KX; Yuan JL; Gao X; Liu CX; Pan TJ; Sun YH;
    Asian J Androl; 2015; 17(6):1017-21. PubMed ID: 25926603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4-10 ng/mL.
    Ng CF; Chiu PK; Lam NY; Lam HC; Lee KW; Hou SS
    Int Urol Nephrol; 2014 Apr; 46(4):711-7. PubMed ID: 24136184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis.
    Ishikawa T; Yoneyama T; Tobisawa Y; Hatakeyama S; Kurosawa T; Nakamura K; Narita S; Mitsuzuka K; Duivenvoorden W; Pinthus JH; Hashimoto Y; Koie T; Habuchi T; Arai Y; Ohyama C
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28241428
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contribution of allelic variability in prostate specific antigen (PSA) & androgen receptor (AR) genes to serum PSA levels in men with prostate cancer.
    Chavan SV; Maitra A; Roy N; Chavan PR
    Indian J Med Res; 2014 Mar; 139(3):371-8. PubMed ID: 24820830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate Health Index density improves detection of clinically significant prostate cancer.
    Tosoian JJ; Druskin SC; Andreas D; Mullane P; Chappidi M; Joo S; Ghabili K; Mamawala M; Agostino J; Carter HB; Partin AW; Sokoll LJ; Ross AE
    BJU Int; 2017 Dec; 120(6):793-798. PubMed ID: 28058757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum level of IGFBP3 and IGF1/IGFBP3 molar ratio in addition to PSA and single nucleotide polymorphism in PSA and CYP17 gene may contribute to early diagnostics of prostate cancer.
    Tajtakova M; Pidanicova A; Valansky L; Lachvac L; Nagy V; Sivonova M; Dobrota D; Kliment J; Petrovicova J
    Neoplasma; 2010; 57(2):118-22. PubMed ID: 20099974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of prostate-specific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study.
    Mearini L; Ferri C; Lazzeri M; Bini V; Nunzi E; Fiorini D; Costantini E; Manasse GC; Porena M
    Urol Int; 2014; 93(2):135-45. PubMed ID: 24732975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prostate Cancer Prevention Trial risk calculator for evaluating the risk of prostate cancer in the high-risk Chinese population].
    Zhu XD; Zheng A; Wang ZQ; Shao Q
    Zhonghua Nan Ke Xue; 2018 Feb; 24(2):142-146. PubMed ID: 30156074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and the prostate health index (PHI) in a Chinese hospital-based biopsy population.
    Na R; Ye D; Liu F; Chen H; Qi J; Wu Y; Zhang G; Wang M; Wang W; Sun J; Yu G; Zhu Y; Ren S; Zheng SL; Jiang H; Sun Y; Ding Q; Xu J
    Prostate; 2014 Nov; 74(15):1569-75. PubMed ID: 25176131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer.
    Wiklund F; Zheng SL; Sun J; Adami HO; Lilja H; Hsu FC; Stattin P; Adolfsson J; Cramer SD; Duggan D; Carpten JD; Chang BL; Isaacs WB; Grönberg H; Xu J
    Prostate; 2009 Mar; 69(4):419-27. PubMed ID: 19116992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel algorithm for the prediction of prostate cancer in clinically suspected patients.
    Gallotta A; Ziglioli F; Ferretti S; Maestroni U; Moretti M; Aloe R; Gnocchi C; Di Palo M; Fassina G
    Cancer Biomark; 2013; 13(4):227-34. PubMed ID: 24240583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Very low PSA concentrations and deletions of the KLK3 gene.
    Rodriguez S; Al-Ghamdi OA; Burrows K; Guthrie PA; Lane JA; Davis M; Marsden G; Alharbi KK; Cox A; Hamdy FC; Neal DE; Donovan JL; Day IN
    Clin Chem; 2013 Jan; 59(1):234-44. PubMed ID: 23169475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate Cancer Risk-Associated Single-Nucleotide Polymorphism Affects Prostate-Specific Antigen Glycosylation and Its Function.
    Srinivasan S; Stephens C; Wilson E; Panchadsaram J; DeVoss K; Koistinen H; Stenman UH; Brook MN; Buckle AM; Klein RJ; Lilja H; Clements J; Batra J;
    Clin Chem; 2019 Jan; 65(1):e1-e9. PubMed ID: 30538125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic performance of expression of PCA3, Hepsin and miR biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer.
    Roberts MJ; Chow CW; Schirra HJ; Richards R; Buck M; Selth LA; Doi SA; Samaratunga H; Perry-Keene J; Payton D; Yaxley J; Lavin MF; Gardiner RA
    Prostate; 2015 Apr; 75(5):539-49. PubMed ID: 25597828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Usefulness of age-specific reference range of prostate-specific antigen for Japanese men older than 60 years in mass screening for prostate cancer.
    Ito K; Yamamoto T; Kubota Y; Suzuki K; Fukabori Y; Kurokawa K; Yamanaka H
    Urology; 2000 Aug; 56(2):278-82. PubMed ID: 10925094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of gene polymorphisms of KLK3 and prostate cancer: A meta-analysis.
    Li H; Fei X; Shen Y; Wu Z
    Adv Clin Exp Med; 2020 Aug; 29(8):1001-1009. PubMed ID: 32869960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients.
    Kader AK; Sun J; Isaacs SD; Wiley KE; Yan G; Kim ST; Fedor H; DeMarzo AM; Epstein JI; Walsh PC; Partin AW; Trock B; Zheng SL; Xu J; Isaacs W
    Prostate; 2009 Aug; 69(11):1195-205. PubMed ID: 19434657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men.
    Oesterling JE; Kumamoto Y; Tsukamoto T; Girman CJ; Guess HA; Masumori N; Jacobsen SJ; Lieber MM
    Br J Urol; 1995 Mar; 75(3):347-53. PubMed ID: 7537604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Additional value of the ratio of serum total testosterone to total prostate-specific antigen in the diagnosis of prostate cancer in a Chinese population.
    Xu L; Hu X; Zhu Y; Lu J; Xu Y; Wang G; Guo J
    Andrologia; 2018 Mar; 50(2):. PubMed ID: 28752596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.